文献速递血栓与止血

细胞应激与凝血因子生成:多未必佳

Cellular stress and coagulation factor production: when more is not necessarily better.
PubMed 文献 · J Thromb Haemost · 2023-10-14

本文综述血友病A和B基因治疗进展,回顾40年来凝血因子VIII和IX基因克隆及重组产品、长效制剂和腺相关病毒载体基因转移方法的发展,重点讨论FVIII在内质网错误折叠与聚集、分泌效率低,以及肝细胞表达激活未折叠蛋白反应可能损害肝细胞功能并潜在驱动肝细胞癌。

要点

  • 血友病A和B基因治疗已获美国食品药品监督管理局批准,采用肝细胞靶向腺相关病毒载体。
  • FVIII较FIX更大,易在内质网错误折叠和聚集,哺乳动物细胞分泌效率低。
  • 因腺相关病毒载体包装容量限制,血友病A基因治疗使用B结构域缺失型FVIII而非全长蛋白。

核心结论

  • 血友病A基因治疗的持久性和安全性问题仍有待解决;FVIII在肝细胞表达激活未折叠蛋白反应,对肝细胞功能与存活不利,并可能驱动肝细胞癌。

研究设计与样本

  • 本文为综述,围绕对FVIII分泌限制因素及肝细胞表达后潜在病理生理后果的当前认识进行论述。

主要发现

  • 血友病A和B的基因分别为编码凝血因子VIII和IX的2个基因,其分离至今已40年。
  • 纯化重组蛋白因子不含人混合血浆污染病毒,降低了既往与人血浆来源凝血因子相关的发病率和死亡率。
  • 已开发出血浆半衰期延长的修饰因子,并开发并获得美国食品药品监督管理局批准肝细胞靶向腺相关病毒载体介导的基因转移方法用于血友病A和B。
  • FVIII较FIX大得多,易在内质网错误折叠和聚集,哺乳动物细胞分泌效率低。
  • 因腺相关病毒载体包装容量限制,血友病A基因治疗使用B结构域缺失型FVIII而非全长蛋白;与全长FVIII一样,B结构域缺失型FVIII错误折叠且分泌效率低。

局限性

  • 血友病A基因治疗的持久性和安全性仍存在重大关切,有待解决。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Remarkably, it has been 40 years since the isolation of the 2 genes involved in hemophilia A (HA) and hemophilia B (HB), encoding clotting factor (F) VIII (FVIII) and FIX, respectively. Over the years, these advances led to the development of purified recombinant protein factors that are free of contaminating viruses from human pooled plasma for hemophilia treatments, reducing the morbidity and mortality previously associated with human plasma-derived clotting factors. These discoveries also paved the way for modified factors that have increased plasma half-lives. Importantly, more recent advances have led to the development and Food and Drug Administration approval of a hepatocyte-targeted, adeno-associated viral vector-mediated gene transfer approach for HA and HB. However, major concerns regarding the durability and safety of HA gene therapy remain to be resolved. Compared with FIX, FVIII is a much larger protein that is prone to misfolding and aggregation in the endoplasmic reticulum and is poorly secreted by the mammalian cells. Due to the constraint of the packaging capacity of adeno-associated viral vector, B-domain deleted FVIII rather than the full-length protein is used for HA gene therapy. Like full-length FVIII, B-domain deleted FVIII misfolds and is inefficiently secreted. Its expression in hepatocytes activates the cellular unfolded protein response, which is deleterious for hepatocyte function and survival and has the potential to drive hepatocellular carcinoma. This review is focused on our current understanding of factors limiting FVIII secretion and the potential pathophysiological consequences upon expression in hepatocytes.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Chen Z, Herzog RW, Kaufman RJ, et al. Cellular stress and coagulation factor production: when more is not necessarily better. J Thromb Haemost. 2023. PMID: 37839613. doi:10.1016/j.jtha.2023.10.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。